Kori Group Plants Digital Healthcare 'China Success DNA' Domestically

Bio healthcare specialist company Kori Group announced on the 12th that it will target the related market domestically by leveraging its successful digital healthcare cases in China.

Kori Group has been interested in 'digital healthcare,' a core keyword of Healthcare 4.0, from the early stages. It currently holds numerous patents including remote medical consultation and deep learning-based technologies, and is developing and advancing related projects based on these.

The first place where Kori Group's digital healthcare was realized is China. Based on over 30 years of accumulated experience in the Chinese medical market, Kori Group was able to achieve success with healthcare services such as 'Life Ofmom' and 'SCSS (Smart Clinic Support System)'.

Life Ofmom is a maternal and child healthcare app that provides comprehensive healthcare services for pregnant women and infants, ranging from gestational diabetes mellitus (GDM) to fetal genetic prevention services, creating a significant impact locally.

SCSS is a cloud-based total solution platform that connects O2O by predicting the demand for online medical systems. It is the only platform of its kind in China, provided free of charge to primary users, the doctors, and is currently used by about 20,000 local medical institutions.

Annual sales related to goods through SCSS exceed 30 billion KRW, and it is rapidly spreading with a goal of reaching 100,000 medical institutions by 2030.

Han Seong-jun, CEO of Evixgen and CTO of both Kori Group and Dx&Vx, said, “Kori Group designated 'Healthcare 4.0' as a future core growth engine several years ago and has quietly focused internal capabilities. We plan to successfully establish a foothold in the domestic market by maximizing the synergy effect of Kori Group’s overseas success know-how, the global network capabilities of the parent group, and the core IT technologies of affiliated companies in digital healthcare.”

Kori Group is one of the subsidiaries of Hanmi Pharmaceutical Group and is affiliated with Dx&Vx.

Some analysts evaluate that the triangular alliance of Kori Group, Hanmi, and Dx&Vx, with over 30 years of accumulated development know-how and a global network, and a corporate valuation of 1.2 trillion KRW, will not only harmonize and create synergy but also lead to trillion-level investments.

Healthcare 4.0, designated as a future core growth engine, is a concept emphasizing universal health coverage for all citizens, centered on patients, with ‘Connected Healthcare’ as the core system.

This enables personalized medical care and health management by linking individuals’ medical and health data to an intelligent healthcare system.

The government is driving innovation in medical services through digital healthcare technologies such as data and AI following the COVID-19 pandemic.

CEO Han Seong-jun emphasized, “If a platform like SCSS, a successful case in China, is linked with the supply chain of Hanmi Pharmaceutical, a top-tier domestic pharmaceutical company, tremendous synergy will occur. This is very meaningful not only for the success of a single pharmaceutical company but also for laying the foundation of a future industry at the national level.”